Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-23T21:14:21.897Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Corticosteroid Therapy on Serum and CSF Malondialdehyde and Antioxidant Proteins in Multiple Sclerosis

Published online by Cambridge University Press:  24 February 2017

M.S. Keles ,
S. Taysi ,
N. Sen ,
H. Aksoy  and
F. Akçay
M.S. Keles*
Affiliation:
Department of Biochemistry, Ataturk University, Faculty of Medicine, Erzurum, Turkey
S. Taysi
Affiliation:
Department of Biochemistry, Ataturk University, Faculty of Medicine, Erzurum, Turkey
N. Sen
Affiliation:
Department of Neurology, Ataturk University, Faculty of Medicine, Erzurum, Turkey
H. Aksoy
Affiliation:
Department of Biochemistry, Ataturk University, Faculty of Medicine, Erzurum, Turkey
F. Akçay
Affiliation:
Department of Biochemistry, Ataturk University, Faculty of Medicine, Erzurum, Turkey
*
Ataturk University, Faculty of Medicine, Department of Biochemistry, Erzurum, Turkey.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

Multiple sclerosis (MS) is a disease characterised by perivascular infiltrates and demyelination of the white matter in the central nervous system. Although the precise cause of MS remains unknown, some investigations have been carried out on antioxidant mechanisms in these patients.

Methods:

In this study, malondialdehyde (MDA), as a lipid peroxidation marker, and ceruloplasmin (Cp) and transferrin (Trf), as antioxidant proteins, levels were determined in cerebrospinal fluid (CSF) and serum of 30 MS patients before and after corticosteroid therapy and in 20 control subjects. Transferrin and Cp levels were measured by the nephelometric method and MDAwas measured spectrophotometrically.

Results:

Mean MDAserum and MDACSF levels were found to be highest in the pretreatment group and lowest in the control group. Although there was no significant difference in terms of serum Trf level, serum Cp was found higher in pre- and posttreatment groups than in the control groups. Ceruloplasmin and Trf levels of CSF were not detectable using the nephelometric method. A significant correlation was found between MDACSF and MDAserum in the pretreatment group (r=0.58).

Conclusions:

These data revealed that lipid peroxidation was increased in serum and particulary in CSF of MS patients and was reduced with corticosteroid therapy.

Résumé:

RÉSUMÉ:Objectif:

La sclérose en plaques (SEP) est une maladie caractérisée par des infiltrats périvasculaires et une démyélinisation de la substance blanche dans le système nerveux central. Bien que la cause précise de la SEP demeure inconnue, des recherches ont porté sur les mécanismes antioxydants chez ces patients.

Méthodes:

Dans cette étude, les taux de malondialdéhyde (MDA), comme marqueur de la peroxydation lipidique, et de céruloplasmine (Cp) et de transferrine (Trf) comme protéines antioxydantes, ont été déterminés dans le liquide céphalorachidien (LCR) et le sérum de 30 patients atteints de SEP, avant et après la corticothérapie, et chez 20 sujets contrôles. Les niveaux de Trf et de Cp ont été mesurés par néphélométrie et les niveaux de MDAont été mesurés par spectrophotométrie.

Résultats:

On a observé les niveaux moyens de MDAdu sérum et du LCR les plus élevés chez le groupe de patients avant le traitement et les plus bas chez le groupe contrôle. Bien qu'il n'y avait pas de différence significative dans les niveaux de Trf sériques, les niveaux de Cp sériques étaient plus élevés chez le groupe SEPavant et après traitement que chez le groupe contrôle. Les niveaux de Cp et de Trf du LCR n'étaient pas détectables par néphélométrie. Il existait une corrélation significative entre les niveaux de MDAdu LCR et du sérum chez le groupe SEPavant traitement (r=0.58).

Conclusions:

Ces données révèlent que la peroxydation lipidique était augmentée dans le sérum et surtout dans le LCR des patients atteints de SEPet était diminuée par la corticothérapie.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 28 , Issue 2 , May 2001 , pp. 141 - 143
Copyright
Copyright © The Canadian Journal of Neurological 2001

References

REFERENCES

1. Raine, CS, Traugott, U. Immunopathology of the lesion in multiple sclerosis and chronic relapsing experimental allergic encephalomyelitis. In: Vandenpark, AA, Paus, JEM, eds. Immunoregulatory Processes in Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Amsterdam: Elsevier, 1984:151–212.Google Scholar
2. Waksman, BH. Mechanisms in multiple sclerosis. Nature (Lond.) 1985; 318:104–105.CrossRefGoogle ScholarPubMed
3. Rogovina, NI, Koklov, AP. Metabolism of lipid peroxidation products in multiple sclerosis patients. Zh Nevropatol Psikhiatr Im S S Korsakova 1980; 80:696–700 (Abstract).Google ScholarPubMed
4. Naidoo, R, Knapp, ML. Studies of lipid peroxidation products in the cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38:2449–2454.CrossRefGoogle ScholarPubMed
5. Roeser, HP, Lee, GR, Nacht, S, Certwright, GE. The role of ceruloplasmin in iron metabolism. J Clin Invest 1970; 49:2408–2417.Google Scholar
6. Gutteridge, JMC, Richmond, R, Halliwell, B. Oxygen free-radicals and lipid peroxidation: inhibition by the protein ceruloplasmin. FEBS Lett 1980; 112:269–272.Google Scholar
7. Yamashoji, S, Kajimoto, G. Antioxidant effect of ceruloplasmin on microsomal lipid peroxidation. FEBS Lett 1983; 152:168–170.Google Scholar
8. Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol 1983; 13:227–231.Google Scholar
9. Link, H, Tibbling, G. Principle of albumin and IgG in neurological disorders. 2. Relation of the concentration of the proteins in serum and the CSF. Scand J Clin Lab Invest 1977; 37:391–395.CrossRefGoogle Scholar
10. Hunter, MIS, Nlemadim, BC, Davidson, DLW. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985; 10:1645–1652.Google Scholar
11. Al-Timimi, DJ, Dormandy, TL. The inhibition autoxidation by human ceruloplasmin. Biochem J 1977; 168:283–288.Google Scholar
12. Newcombe, J, Li, H, Cuzner, ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Appl Neurobiol 1994; 20:152–162.CrossRefGoogle ScholarPubMed
13. Calabrase, V, Raffaele, R, Cosentino, E, Rizza, V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res 1994; 14:119–123.Google Scholar